Completed PHASE3 INTERVENTIONAL 2-arm NCT04709536

A Study of IBI306 in Participants With Hypercholesterolemia

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of IBI306 in Patients With Hypercholesterolemia in China (CREDIT-4)

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Conditions Hypercholesterolemia

Interventions IBI306 Placebo

Updated 6 times since 2021 Last updated: Oct 29, 2024 Started: Feb 9, 2021 Primary completion: Nov 9, 2021 Completion: Jan 28, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hypercholesterolemia, this trial is completed. The trial is conducted by Innovent Biologics (Suzhou) Co. Ltd. and has accumulated 6 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Nov 2024 — Present [monthly]

Completed PHASE3

Status: Unknown → Completed
Sep 2024 — Nov 2024 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
May 2023 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
May 2021 — May 2023 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Feb 2021 — May 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Innovent Biologics (Suzhou) Co. Ltd.

Data source: Innovent Biologics (Suzhou) Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China